glp-1 telehealth crackdown news today The FDA is cracking down on ‘misleading’ compounded GLP-1s from companies., Compounded weight loss drugs are not FDA-approved, which means the agency does not review their safety, National Hispanic Medical Association |

About this article Cite this article Dong, C., Yang, Y., Cheng, B

Patients and providers should treat them as directional rather than definitive, and decisions about participating in trials or accessing investigational therapies should always involve a specialist in endocrinology or metabolic medicine

This stability enables consistent dosing and reliable preclinical investigation

Further studies should be performed in HF patients to address the current limitations of completed animal studies including concerns with infection and rejection

The previous twice-daily formulation faced challenges in Phase 2b testing, leading to its discontinuation